This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Altria (MO) Q3 Earnings Miss Estimates, Revenues Down Y/Y
by Zacks Equity Research
Altria's (MO) third-quarter performance is affected by lower shipment volumes in the smokeable and oral tobacco categories. Nevertheless, higher pricing in these categories is an advantage.
Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DHS
Should WisdomTree U.S. Dividend exFinancials ETF (DTN) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DTN
Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DHS
How Has Philip Morris' Q3 Earnings Beat Impacted Staples ETFs?
by Sweta Jaiswal, FRM
Here we highlight some consumer staples ETFs with significant exposure to Philip Morris (PM) since its earnings release.
Is WisdomTree U.S. Dividend exFinancials ETF (DTN) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DTN
Stock Market News for Oct 20, 2021
by Zacks Equity Research
The S&P 500 and Nasdaq recoded the largest four consecutive winning stretch since July, lifted by an encouraging third-quarter corporate earnings result.
Philip Morris (PM) Q3 Earnings & Revenues Beat Mark, Rise Y/Y
by Zacks Equity Research
Philip Morris' (PM) third-quarter 2021 results reflect higher earnings and revenues with favorable pricing variance being an upside.
Philip Morris (PM) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Philip Morris (PM) delivered earnings and revenue surprises of 2.60% and 3.09%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Philip Morris (PM) Queued for Q3 Earnings: Things to Note
by Zacks Equity Research
Philip Morris' (PM) Q3 results are likely to reflect gains from pricing as well as strength in reduced risk products. The duty-free business might have been affected by the pandemic-led uncertainties.
Philip Morris' (PM) IQOS, Beyond Nicotine Growth Plans On-Track
by Zacks Equity Research
Philip Morris (PM) benefits from the growing market for IQOS devices globally. It is also focused on the expansion of Beyond Nicotine products to support inhaled therapeutics.
Focus on Low-Risk Offerings Drives Altria (MO), Pricing Aids
by Zacks Equity Research
Altria (MO) strives to expand IQOS and on! amid consumers' rising preference on low-risk tobacco alternatives. Moreover, strong pricing for tobacco products is driving revenues.
Philip Morris (PM) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Philip Morris (PM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights: Philip Morris, Altria Group and Turning Point Brands
by Zacks Equity Research
Zacks Industry Outlook Highlights: Philip Morris, Altria Group and Turning Point Brands
3 Tobacco Stocks to Watch Out For on RRPs and Pricing Gains
by Vidya Nair
The Zacks Tobacco industry gains from reduced-risk products and solid pricing. Such upsides have been benefiting companies like Philip Morris (PM), Altria (MO) and Turning Point Brands (TPB). However, regulatory headwinds in cigarettes are a concern.
Top Research Reports for Microsoft, Amazon & NextEra Energy
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Amazon.com, Inc. (AMZN), and NextEra Energy, Inc. (NEE).
Philip Morris (PM) Strives to Expand IQOS & Beyond Nicotine
by Zacks Equity Research
Philip Morris (PM) is gaining from growing consumer acceptance for IQOS devices. It is on track with the expansion of Beyond Nicotine products to support inhaled therapeutics.
Philip Morris (PM) Secures More than 74% Stake in Vectura
by Zacks Equity Research
Philip Morris (PM) secures more than 74% of Vectura's shares to become a majority stakeholder. The company expects to amplify growth in its Beyond Nicotine strategy via this move.
Philip Morris (PM) Buys Fertin Pharma, Announces Dividend Hike
by Zacks Equity Research
Philip Morris (PM) buys Fertin Pharma to attain its target of becoming a majority smoke-free company by 2025. The company also raises its quarterly dividend.
Altria (MO) Benefits From Low-Risk Products, High Pricing
by Zacks Equity Research
Altria (MO) is gaining from rising popularity of IQOS and on!. Strong pricing for tobacco products is also driving revenue growth.
The Zacks Analyst Blog Highlights: Adobe, Thermo Fisher, BHP Group, Philip Morris and Chubb
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Adobe, Thermo Fisher, BHP Group, Philip Morris and Chubb
Top Stock Reports for Adobe, Thermo Fisher & BHP Group
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE), Thermo Fisher Scientific Inc. (TMO), and BHP Group (BHP).
Philip Morris (PM) Gains on IQOS, Beyond Nicotine Expansion
by Zacks Equity Research
Philip Morris (PM) is gaining from rising popularity of IQOS devices. The company is also progressing with the expansion of Beyond Nicotine products that cater to medical wellness.
Altria (MO) Hikes Dividend, Boosts Shareholders' Wealth
by Zacks Equity Research
Altria (MO) raises quarterly dividend by 4.7% to 90 cents per share. The company's new annualized dividend rate is $3.60 per share.
Factors Likely to Influence Brown-Forman's (BF.B) Q1 Earnings
by Zacks Equity Research
Brown-Forman's (BF.B) Q1 results are expected to reflect gains from strong underlying sales across regions, brand investments, and the reopening of on-premise and tourism across several markets.